The information and contents of this Biological Agent Reference Sheet (including all text and graphics), whether available in print or electronic format (including any digital format, e-mail transmissions, or download from the website), shall be known hereinafter as “Reference Sheet Content”. The Reference Sheet Content is provided as a courtesy and is not intended as a sole source of guidance in the evaluation of Biological Agents. The Reference Sheet Content is not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from a physician or health care provider. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not rely on the Reference Sheet Content for diagnosis, treatment, or medical advice. This Reference Sheet Content is for informational purposes and does not provide individualized medical care or treatment. No endorsement of any specific tests, products, or procedures is made by Reference Sheet Content or affiliated party, member, agent or employee of the Emory University Environmental Health and Safety Office.
**CHARACTERISTICS**

**Morphology**
Vibrio cholerae (VC) is a gram negative, non-spore forming, curved rod. There are many serogroups of V. cholerae, but only two – O1 and O139 – cause outbreaks. V. cholerae O1 (VC O1) has caused all recent outbreaks.

**Growth Conditions**
Cary Blair media is ideal for transport, and the selective thiosulfate–citrate–bile salts agar (TCBS) is ideal for isolation and identification.

**HEALTH HAZARDS**

**Host Range**
Humans, water birds, shellfish, fish, and herbivores have been found to contain the infectious agent

**Modes of Transmission**
Consumption of contaminated food or water. Symptomatic patients may shed Vibrio before clinical signs of illness and up to 2 weeks after, whereas asymptomatic patients typically only shed Vibrio for 1 day.

**Reservoirs**: The bacterium has been found in birds and herbivores surrounding freshwater lakes and rivers as well as in algae, copepods (zooplankton), crustaceans and insects.

**Signs and Symptoms**
Only 5-10% of persons infected with VC O1 may have illness requiring treatment at a health center. Symptoms include profuse watery diarrhea, vomiting, rapid heart rate, low blood pressure, dehydration, muscle cramps, irritability.

**Infectious Dose**
The infectious dose ranges between $10^9$ and $10^{11}$ ingested Vibrio.

**Incubation Period**
Ranges from a few hours to 5 days after infection

**MEDICAL PRECAUTIONS / TREATMENT**

**Prophylaxis**
Hand washing

**Vaccines**
FDA recently approved a single dose live oral cholera vaccine for use in the United States. It has been approved for vaccination of adults 18-64 yr old who are traveling to an area of active cholera.

**Treatment**
VC is susceptible to antibiotics.

**Surveillance**
Monitor for symptoms. Confirm diagnosis by dark field microscopy of a wet mount of fresh stool, PCR or ELISA

**Emory Requirements**
Report all exposures. Cholera is a U.S. nationally reportable disease.

**LABORATORY HAZARDS**

**Laboratory Acquired Infections (LAIs)**
Rare cases of bacterial enteritidis due to LAI with either V. cholerae or V. parahaemolyticus have been reported

**Sources**
Pathogenic Vibrio can be found in human fecal samples or in contaminated shellfish. Accidental ingestion of VC results from eating with contaminated hands, using contaminated syringes or the handling of contaminated marine samples without gloves.

**SUPPLEMENTAL REFERENCES**


CDC - https://www.cdc.gov/cholera
https://www.cdc.gov/biosafety/publications/bmbl5/

**CONTAINMENT**

**BSL2/ABSL2**
Containment Level 2 facilities, equipment, and operational practices. **No open-bench work** should be performed with VC. All work should be performed inside a Biosafety Cabinet. Use of needle-safe sharps is encouraged. Centrifuge rotors must have a lid, samples should be loaded/unloaded inside the BSC and the centrifuge should be disinfected with appropriate disinfectant after use.

**ABSL2 practices, containment and equipment are recommended for experimentally infected animals.**

**SPILL PROCEDURES**

**Small**
Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply an EPA approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before disposal and cleanup of spill materials.

**Large**
Contact Emory’s Biosafety Officer (404-727-8863), the EHSO Office (404-727-5922), or the The Spill Response Team (404-727-2888).

**EXPOSURE PROCEDURES**

**Mucous membrane**
Flush eyes, mouth or nose for 15 minutes at eyewash station.

**Other Exposure**
Wash area with soap and water for 15 minutes.

**Reporting**
Immediately report incident to supervisor, complete an employee incident report in PeopleSoft.

**Medical Follow up**

<table>
<thead>
<tr>
<th>Time</th>
<th>Contact</th>
<th>Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>7am-4pm (OIM):</td>
<td>EUH (404-686-7941) WW (404-728-6431)</td>
<td>After Hours: OIM NP On Call 404-686-5500 PIC# 50464</td>
</tr>
</tbody>
</table>

**VIABILITY**

**Disinfection**
2% chlorine, 0.5% chlorine, 0.05% chlorine

**Inactivation**
VC can be inactivated by cold (loss of viability after a cold shock at 0°C).

**Survival**
*V. cholerae* can survive in well water for 7.5 ± 1.9 days and the El Tor biotype can survive 19.3 ± 5.1 days

**PERSONAL PROTECTIVE EQUIPMENT (PPE)**

**Minimum PPE Requirements**
At minimum, personnel are required to don gloves, closed toed shoes, lab coat, and appropriate face and eye protection prior to working with *V. cholerae*. Additional PPE may be required depending on lab specific SOPs.

**Additional Precautions**
Use respiratory protection if work will be performed outside the biosafety cabinet. Additional precautions should be considered with work involving animals or large scale activities.